| Document |
Document Title |
|
WO/2023/154980A1 |
A method for treating a subject having a retinal eye condition that is refractory to anti-VEGF treatments is disclosed. The method comprises administering a therapeutically effective amount of one or more steroids subsequent to anti-VEGF...
|
|
WO/2023/155828A1 |
The present invention relates to a modified adeno-associated virus (AAV) capsid polypeptide and a novel recombinant adeno-associated virus (rAAV) comprising the modified AAV capsid polypeptide for delivering the gene product for the ther...
|
|
WO/2023/155756A1 |
Disclosed in the present invention is the use of a lipoic acid nanoparticle in the preparation of a drug for treating diseases related to oxidative stress, which belongs to the technical field of biomedicine. The drug for treating diseas...
|
|
WO/2023/156487A1 |
Tears are a complex biological fluid secreted by the lacrimal apparatus. Their composition can change according to the context. After a corneal wound, the lacrimal gland secretes reflex tears, which contain specific growth factors suppor...
|
|
WO/2023/158286A1 |
The present invention pertains to a calsequestrin-based metal ion reactive particle and uses thereof. More specifically, the present invention pertains to: a calsequestrin-based metal ion reactive particle prepared by binding a physiolog...
|
|
WO/2023/156730A1 |
The subject matter of the present invention is new conjugates of general formula (I) as defined in claim 1. The conjugates of the invention comprise 1/ at least one mannose 6-phosphate (M6P) analogue which targets the cation-independent ...
|
|
WO/2023/154964A1 |
The present disclosure provides oligonucleotides (e.g., antisense oligonucleotides and RNA interference (RNAi) oligonucleotides) directed to target nucleic acids encoding EFEMP1 and methods for use of the oligonucleotides or compositions...
|
|
WO/2023/151600A1 |
Provided is a polypeptide capable of dissolving protein aggregates. Also provided is a method of treating a phase separation associated diseases, such as phase separation associated visual disorders (e.g., cataracts) using the polypeptid...
|
|
WO/2023/152387A1 |
The invention relates to a topical composition comprising, as an active ingredient, a mixture of hyaluronic acid, trehalose and an extract of roots of Ophiopogon japonicus for use as a soothing agent and/or moisturizer for eyelids and/or...
|
|
WO/2023/151788A1 |
The present invention relates to a composition for use in the treatment and/or prophylaxis of a lipofuscin-associated disease, wherein the composition comprises melanin and/or induces melanogenesis.
|
|
WO/2023/120536A9 |
To provide a vector and a method widely applicable to the treatment of various genetic diseases or the correction of many mutations. A method for inserting a desired nucleic acid into a nucleic acid in a cell by cleaving a target nucleic...
|
|
WO/2023/152263A1 |
The present invention relates to a composition for use in the treatment and/or prophylaxis of a lipofuscin-associated disease, wherein the composition comprises melanin and/or induces melanogenesis.
|
|
WO/2023/153535A1 |
A syringe containing an ophthalmic formulation provided. A syringe containing an ophthalmic formulation, of the present invention, has excellent storage properties, and thus can maintain drug efficacy even for long term storage. The stru...
|
|
WO/2023/150791A1 |
The present disclosure includes methods of treating an ocular disease or condition at the surface of the eye, including ocular diseases that involve the cornea. More specifically the present disclosure relates to treating an ocular disea...
|
|
WO/2023/148180A1 |
The present invention concerns an ophthalmic composition comprising: - hyaluronic acid, or one of its salts, advantageously of a molecular weight comprised between 100 and 800 kDa; - an oligosaccharide, advantageously a diholoside, more ...
|
|
WO/2023/148016A1 |
The present invention relates to a method of predicting responsiveness to an inhibitor of the kallikrein-kinin pathway, such as plasma kallikrein inhibitors, in subjects with diabetic macular edema.
|
|
WO/2023/149420A1 |
The present disclosure relates to a method for preventing or treating myopia and a composition to be used in this method. The present inventors found that VEGF deficiency induces loss of the choroidal capillary plate and choroidal thinni...
|
|
WO/2023/148417A1 |
The present invention relates to the oil of the wild olive (fruit of the wild olive tree, Olea europaea L. var. sylvestris or oleaster) for use in the prevention and treatment of ocular hypertension and eye diseases caused by high intrao...
|
|
WO/2023/150142A1 |
The present disclosure provides a construct comprising a coding sequence operably linked to a promoter, wherein the coding sequence encodes a vascular endothelial growth factor (VEGF) binding agent or a portion thereof. In some embodimen...
|
|
WO/2023/148231A1 |
The present invention relates to aqueous cyclodextrin compositions containing drug/cyclodextrin complexes and sorbic acid or a pharmaceutically acceptable sorbate that exhibit a superior antimicrobial preservation effect at a low preserv...
|
|
WO/2023/150085A1 |
Platelet-derived extracellular vesicles that include mitochondria (PEVs) are used in the treatment of an ocular disorder, or a symptom of the ocular disorder. The PEVs are collected by obtaining blood from one or more donors, adding an a...
|
|
WO/2023/143366A1 |
A variant adeno-associated virus and the use thereof in gene treatment and cell regeneration of a mediated cochlea. The variant adeno-associated virus can efficiently transduce hair cells and/or support cells in the cochlea, promotes reg...
|
|
WO/2023/145735A1 |
Provided is a new therapy/prevention for aging-related disorders including sarcopenia. The present invention pertains to a pharmaceutical composition that contains an expectorant (examples thereof include compounds, or pharmaceutically a...
|
|
WO/2023/143452A1 |
The present invention provides an application of a steroidal compound in the preparation of a drug for preventing and/or treating cataracts. The steroidal compound provided by the present invention can have good treatment, alleviation an...
|
|
WO/2023/144330A1 |
The present invention is inter alia directed to artificial nucleic acid constructs, preferably RNA, comprising at least one coding sequence encoding at least one transcription factor inhibitor for reducing or inhibiting the activity of a...
|
|
WO/2023/143476A1 |
Provided herein are deuterated ROCK inhibitors, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a d...
|
|
WO/2023/147312A1 |
Compounds and methods of using the same for treating conditions alleviated by AMPK activation are provided.
|
|
WO/2023/143575A1 |
The present invention relates to an M-choline receptor agonist compound as shown in formula (A), and to a preparation method therefor and a use thereof. The compound shown in formula (A) of the present invention has a significant effect ...
|
|
WO/2023/145873A1 |
The present invention pertains to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. (The definitions of R1, R2, L, m and n in formula (I) are stated in the specification.)
|
|
WO/2023/145831A1 |
This invention includes, e.g., a pharmaceutical composition serving to treat retinitis pigmentosa and containing nanoparticles in which statin is encapsulated.
|
|
WO/2023/141681A1 |
The present invention relates to isolated or purified antisense oligonucleotides that bind to intron 7 of an OPA1 gene pre-mRNA. The present invention also relates to methods of manipulating translation of the OPA1 gene transcript and us...
|
|
WO/2023/144030A1 |
The present invention relates to the use of plasma kallikrein inhibitors for sensitizing patients having an ophthalmic disorder to anti-VEGF therapy and to provide an increased effect of anti-VEGF therapy.
|
|
WO/2023/144053A1 |
Compounds of the formula (I) Q1-Q2-Q3 in which Q1, Q2 and Q3 have the meanings indicated in Claim 1, degrade target proteins, and can be employed, inter alia, for the treatment of diseases such as cancer, multiple sclerosis, cardiovascul...
|
|
WO/2023/143470A1 |
The present invention relates to the field of biotechnology. Disclosed are a bifunctional fusion protein, a method for preparing same, and use thereof. The bifunctional fusion protein comprises a VEGF antagonist fragment and a TGF-β ant...
|
|
WO/2023/138066A1 |
Provided in the present invention is the use of an anti-EGFR antibody in the preparation of a drug for preventing and/or treating diseases related to ocular angiogenesis.
|
|
WO/2023/141249A1 |
An implantable device for delivery of a tyrosine kinase inhibitor is provided. The device comprises a core defining an outer peripheral surface. The core comprises a core polymer matrix within which is dispersed a tyrosine kinase inhibit...
|
|
WO/2023/139534A1 |
Provided herein are compounds of formula (I) and pharmaceutical compositions thereof useful for treating diseases or disorders mediated by the complement factor B. (I).
|
|
WO/2023/137672A1 |
L-N-isobutyryl cysteine (L-NIBC) -bound gold cluster Au 18 (L-NIBC) 14, its use for treating multiple sclerosis, Alzheimer's disease (AD), liver cirrhosis, diabetes, Parkinson's disease (PD) or glaucoma, and the use of it for manufacturi...
|
|
WO/2023/137671A1 |
L-N-isobutyryl cysteine (L-NIBC) -bound gold cluster Au 15 (L-NIBC) 13, its use for treating multiple sclerosis, Alzheimer's disease (AD), liver cirrhosis, diabetes, Parkinson's disease (PD) or glaucoma, and the use of it for manufacturi...
|
|
WO/2023/139581A1 |
Compounds represented by Formula I: (I) wherein A, B, W, V, Z, Ra, Rb, n and m are as defined in the instant specification, or by Formula la, lb, III, IV or V, as defined in the instant specification, and uses thereof in modulating an ac...
|
|
WO/2023/138592A1 |
Provided in the present invention are a salt form crystal form of a pyrimidine derivative and a preparation method therefor, which belong to the field of chemistry. The crystal form of the pyrimidine derivative is an ethanolamine salt cr...
|
|
WO/2023/140357A1 |
The present invention provides an aqueous liquid formulation which contains: arbekacin and/or a salt thereof; and at least one water-soluble polymer that is selected from the group consisting of a hydroxypropylmethyl cellulose, a hydroxy...
|
|
WO/2023/141334A2 |
Pharmaceutical compositions and methods for treating ocular disorders in a subject, which include betamethasone or a pharmaceutically acceptable salt thereof at a concentration of 0.01% w/w to 0.08% w/w, mycophenolic acid or a pharmaceut...
|
|
WO/2023/139091A1 |
Identification of small organic molecules capable of stimulating aerobic glycolysis and cone survival would lead to the conception of new therapies of the retinal degenerative diseases.Now the inventors identified Geralexin, an acetogeni...
|
|
WO/2023/141251A1 |
A method for prohibiting and/or treating an eye condition is provided. The method comprises inserting an implantable device into a suprachoroidal space of a patient. The device comprises a core defining an outer peripheral surface. The c...
|
|
WO/2023/141631A2 |
Improved methods for treating ophthalmic disorders, particularly those associated with ocular hypertension and glaucoma. Methods of treatment and pharmaceutical compositions for treatment of ophthalmic disorders employing one or more bet...
|
|
WO/2023/140275A1 |
The present invention addresses the problem of providing an antifungal eye drop, particularly, an aqueous eye drop, the eye drop containing luliconazole as an active ingredient. The problem is solved by the eye drop which contains: 1) lu...
|
|
WO/2023/134658A1 |
The invention provides for a composition, which in particular comprising a fusion molecule comprising a least one DNA binding protein and at least one modulator of gene expression, wherein the fusion molecule is targeted to a genomic reg...
|
|
WO/2023/136470A1 |
The present disclosure relates to a novel PNA monomer and PNA oligomer, in which a primary amine contained in a lysine residue, the N-terminus, or the C-terminus of the PNA oligomer is modified to maintain the positive charge of the PNA ...
|
|
WO/2023/135207A1 |
The present invention relates to a pharmaceutical combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof, prodrug thereof or a metabolite thereof with a S1P receptor modulator or a pharmaceutically accepta...
|
